Urinary kallikrein activity in workers exposed to cadmium, lead, or mercury vapour.
A significant reduction of kallikrein activity in urine (assayed by its amidolytic activity) was found in 64 normotensive workers who had been exposed to cadmium for 11 years on average and whose cadmium concentrations in urine ranged from 2.2 to 33.1 micrograms/g creatinine. The mean (geometric) urinary kallikrein activity (in U/g creatinine) amounted to 0.52 (range 0.11-1.90) in the control group (n = 193) against 0.39 (range 0.10-1.03) in the cadmium group, and the prevalence of abnormally low activity levels (less than or equal to 0.20 U/g creatinine) amounted to 17.2% in the cadmium group against 5.2% in the control group. A reduction of aldosterone release (aldosterone in urine) associated with an increased natriuresis was also observed. This might constitute a compensatory mechanism maintaining blood pressure in the normal range. These biological effects of cadmium were not reversible after removal from exposure. This study indicates that cadmium can induce an irreversible toxic effect in the distal nephron. It also suggests that an excessive cadmium body burden alone may not be sufficient to induce hypertension, but in individuals whose blood pressure regulation may be impaired by other factors cadmium could stimulate the development of hypertension. This study also supports the recommendation to prevent hypertensive subjects from being exposed to cadmium. There was no indication that moderate exposure to mercury vapour (n = 53; mercury in urine, range 11-224 micrograms/g creatinine; average duration of exposure: six years) or to inorganic lead (n = 23; lead in blood, range 40-67 micrograms/100 ml; average duration of exposure: eight years) was associated with a reduction of kallikrein production by the kidney.
Roels
H A
HA
Unité de Toxicologie Industrielle et Médecine du Travail, School of Medicine, Catholic University of Louvain, Brussels, Belgium.
Lauwerys
R R
RR
Buchet
J P
JP
Bernard
A M
AM
Lijnen
P
P
Van Houte
G
G
D000328:Adult; D000450:Aldosterone / Q000652:urine; D002104:Cadmium / Q000009:adverse effects* / Q000652:urine; D004781:Environmental Exposure; D006801:Humans; D007610:Kallikreins / Q000652:urine*; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D007854:Lead / Q000009:adverse effects*; D008297:Male; D008628:Mercury / Q000009:adverse effects*; D011188:Potassium / Q000097:blood; D012964:Sodium / Q000097:blood / Q000652:urine
D002104:Cadmium; D007854:Lead; D000450:Aldosterone; D012964:Sodium; D007610:Kallikreins; D008628:Mercury; D011188:Potassium